Who are Compazine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Quetiapine and Topiramate, Pramipexole (Mirapex), LYBALVI, Aripiprazole Augmentation, Adjunctive asenapine, Placebo Asenapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prochlorperazine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Compazine — Competitive Intelligence Brief

Compazine (PROCHLORPERAZINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phenothiazine. Area: Neuroscience.

marketed Phenothiazine D(2) dopamine receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Compazine (PROCHLORPERAZINE) — GSK.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Compazine TARGET	PROCHLORPERAZINE	GSK	marketed	Phenothiazine	D(2) dopamine receptor	1956-01-01
Quetiapine and Topiramate	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Pramipexole (Mirapex)	Pramipexole (Mirapex)	Massachusetts General Hospital	marketed	Dopamine agonist	D2 dopamine receptor, D3 dopamine receptor
LYBALVI	LYBALVI	Alkermes, Inc.	marketed	Atypical antipsychotic with opioid antagonist	D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor
Aripiprazole Augmentation	Aripiprazole Augmentation	Centre for Addiction and Mental Health	marketed	Atypical antipsychotic / dopamine partial agonist	D2 dopamine receptor, 5-HT1A serotonin receptor
Adjunctive asenapine	Adjunctive asenapine	Lori Davis, MD	marketed	Atypical antipsychotic	D2 dopamine receptor, 5-HT2A serotonin receptor
Placebo Asenapine	Placebo Asenapine	Organon and Co	phase 3	Atypical antipsychotic	D2 dopamine receptor, 5-HT2A serotonin receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phenothiazine class)

· 3 drugs in this class
Bristol-Myers Squibb · 2 drugs in this class
GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Compazine — Competitive Intelligence Brief. https://druglandscape.com/ci/prochlorperazine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab